PT Kalbe Farma Tbk Stock INDONESIA S.E.
Equities
KLBF
ID1000096803
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- IDR | - |
Apr. 01 | PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 20 | Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy | MT |
Sales 2024 * | 32,452B 2.01B | Sales 2025 * | 35,129B 2.18B | Capitalization | 67,302B 4.17B |
---|---|---|---|---|---|
Net income 2024 * | 3,439B 213M | Net income 2025 * | 3,572B 221M | EV / Sales 2024 * | 1.97 x |
Net cash position 2024 * | 3,311B 205M | Net cash position 2025 * | 5,337B 331M | EV / Sales 2025 * | 1.76 x |
P/E ratio 2024 * |
21.2
x | P/E ratio 2025 * |
19
x | Employees | - |
Yield 2024 * |
2.18% | Yield 2025 * |
2.34% | Free-Float | 40.45% |
Managers | Title | Age | Since |
---|---|---|---|
Vidjongtius
CEO | Chief Executive Officer | 59 | 96-12-31 |
Chairman | 62 | 97-02-28 | |
Danny Natalies
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Santoso Oen
BRD | Director/Board Member | 59 | 99-12-31 |
Chairman | 62 | 97-02-28 | |
Ronny Hadiana
BRD | Director/Board Member | 52 | 14-12-31 |
1st Jan change | Capi. | |
---|---|---|
+33.25% | 699B | |
+25.41% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.91% | 236B | |
+4.91% | 198B | |
-10.47% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- KLBF Stock
- KLBF Stock